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Abstract
Antiretroviral therapy (ART) requires lifelong daily oral therapy. While patient characteristics associated with
suboptimal ART adherence and persistence have been described in cohorts of HIV-infected persons, these
factors are poor predictors of individual medication taking behaviors. We aimed to create and test instruments
for the estimation of future ART adherence and persistence for clinical and research applications. Following
formative work, a battery of 148 items broadly related to HIV infection and treatment was developed and
administered to 181 HIV-infected patients. ART adherence and persistence were assessed using electronic
monitoring for 3 months. Perceived confidence in medication taking and self-reported barriers to adherence
were strongest in predicting non-adherence over time. Barriers to adherence (e.g., affordability, scheduling)
were the strongest predictors of non-adherence, as well as 3- and 7-day non-persistence. A ten-item battery for
prediction of these outcomes (www.med.unc.edu/ncaidstraining/adherence/for-providers) and a 30-item
battery reflective of underlying psychological constructs can help identify and study individuals at risk for
suboptimal ART adherence and persistence.
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Introduction
Advances in antiretroviral therapy (ART) have significantly improved the prognosis and quality of life of persons
living with HIV infection, and developments in therapeutics, including fixed-dose combination formulations and
single tablet regimens, have simplified ART without compromising efficacy. However, the success of ART
continues to hinge on adequate adherence and persistence to these medications, which, at present, require
lifelong daily dosing.
Suboptimal adherence to treatment and care remains a challenge for many patients, even in the era of modern
ART, and can lead to virologic failure, drug resistance, and transmission of the virus [[1] –[4] ]. Studies conducted
in disparate HIV-infected populations reveal that medication taking behaviors can vary considerably, are
complex, and influenced by personal, institutional, and structural factors [[1] , [2] , [5] –[9] ]. Mental health
challenges, substance abuse, poor social support, unstable housing, denial, stigmatization, regimen complexity,
and cost have each been associated with sub-optimal ART adherence [[1] , [2] ]. These correlates of ART
adherence, derived from cohort studies, are useful when examining populations, but are imperfect predictors of
ART adherence at the individual level. Therefore, clinicians are frequently left to rely on judgment and intuition
when assessing the likelihood of a patient taking their medication regularly—resulting in inaccurate predictions
of patient adherence [[10] ].
Using two scale development approaches, we aimed to create and test an instrument that would allow clinicians
and researchers to estimate future adherence and persistence to ART. We recruited a diverse sample of HIVinfected outpatients receiving care and recruited patients in clinics located in North Carolina, a state with the
eighth highest HIV prevalence rate in the United States. We reasoned that this new instrument could be used to
identify patients/participants at risk for missing ART doses and, therefore, could also identify candidates for
interventions to support adherence and prevent treatment failure.

Methods
Survey Development

The survey development process included three phases: Formative, Instrument Development, and Instrument
Piloting and Testing. The University of North Carolina at Chapel Hill (UNC-Chapel Hill) Biomedical Institutional
Review Board approved all phases.

Formative Phase

Individual semi-structured interviews were conducted with 21 stakeholders in North Carolina, including staff
(e.g., physicians, nurses, social workers) at major HIV clinics and AIDS service organizations, and state health
officials involved in HIV-related policy-making, to assess their perspectives regarding challenges to ART
adherence. Subsequently, six focus groups were conducted among 56 HIV-infected patients who had been
prescribed ART, and were at least 18 years of age. Two focus groups were organized in each of three
geographically distinct areas of North Carolina, including a major metropolitan center, a smaller city, and a rural
county. One focus group was conducted in Spanish. Participants were recruited via flyers placed in HIV clinics
and community service organizations located in these areas. The focus group guide was informed by the
stakeholder responses and the published literature on ART adherence challenges and was designed to explore
attitudes regarding ART among those living with the virus. Findings from the Formative Phase were previously
reported [[11] , [12] ].

Instrument Development Phase

Focus group data were coded and analyzed to identify themes related to the experience of taking ART. The
identified themes were used to generate survey items—statements that could be read or spoken to elicit a
response. In total, 94 Likert-type items with a five-point agreement scale (1 = strongly disagree; 5 = strongly
agree) and 11 contingency questions, which included an additional response option of does not apply, were
combined to create a final battery of items. To gain a better understanding of these items and how they might
be understood by our sample, cognitive interviews were conducted with 18 HIV-positive patients receiving care
at the University of North Carolina (UNC) Infectious Diseases Clinic. The HIV Treatment Adherence Self-Efficacy
Scale (HIV-ASES) [[13] ] and a modified version of the AIDS Clinical Trials Group Adherence Barriers
Questionnaire (ACTG-ABQ) (dichotomous yes/no responses were used instead of the original four-point Likert
scale) [[14] ] were also administered. At the end of this phase of instrument development, 148 items were
included in a question battery for use in the Instrument Piloting and Testing Phase.

Instrument Piloting and Testing Phase

The question battery was piloted with 60 HIV-infected patients receiving care at one of four HIV treatment
centers: the UNC-Chapel Hill Infectious Diseases Clinic, the Wake County Early Intervention Clinic in Raleigh, the
Wake Forest Medical Center Infectious Diseases Clinic in Winston-Salem, and the Regional Center for Infectious
Diseases in Greensboro. The inclusion criteria were as follows: age 18 years or older, English speaking, able to
provide informed consent, receiving ART, not using a pill box, and not residing in an institutional setting where
medications are directly administered. The derived instrument is intended to be used in patients with unknown
levels of adherence. There was no adherence inclusion criterion as a broad spectrum of pill-taking behaviors was
sought to allow for determination of item performance and discrimination. Responses from patients with high
levels of adherence and persistence were necessary to identify response patterns that are predictive of
suboptimal adherence. As with prior stages of the instrument development process, participants were recruited
using flyers placed in HIV clinics and community service organizations. Interested patients called a research
number and were screened by a research associate not associated with the recruitment clinics.

Following the survey piloting, minor wording changes were made to the survey battery. An additional 121
patients meeting the same inclusion criteria for the pilot were recruited using identical procedures at the same
four HIV treatment centers to assess the predictive performance of the items in relation to ART adherence and
persistence. As described in detail below, participants were followed for 3 months during which ART adherence
was assessed. The results from the combined samples from the piloting and testing phases (60 + 121) are
reported in this manuscript.

Study Procedures
Assessments: Instrument Piloting and Testing Phase

For this study phase, participants were screened by research associates who were not associated with the clinics
from which participants were recruited. Those confirmed to be eligible completed a baseline study visit during
which the battery of items was administered using a tablet computer that the participant used to indicate their
responses. At the visit, an electronic medication monitoring cap (MEMs, Aardex Inc) was placed on one HIV
medication bottle. The MEMs cap was placed preferentially on the antiretroviral that the patient self-reported
as most demanding for them; typically this was the medication that required the greatest number of doses per
day, number of pills per day, or largest pill.
After the baseline visit, participants were seen at a mutually agreed upon location where the study visit could be
conducted safely and confidentially at monthly intervals for 3 months. ART adherence and persistence were
assessed by MEMs in the Instrument Piloting and Test Phase. The visual analog scale was used to assess baseline
ART adherence among those entering the study on HIV therapy [[15] ].
Demographic characteristics, self-reported health status, HIV and medical history, ART taking practices (i.e., pill
box use, pocketed doses), motivation to adhere to ART, substance use, and depression were obtained at
baseline by a trained project staff member via computer assisted patient interviewing (CAPI). At each follow-up
visit, changes in health and medication were recorded.

Data Analytic Approach
Quantifying Adherence and Persistence

To assess a participant’s non-adherence, a ratio was calculated as the total number of non-adherent days
divided by the number of days the participant was monitored by MEMs cap. If the number of bottle openings
matched or exceeded the expected dose frequency, then the daily adherence was considered a success. A
participant with a scheduled, twice daily dose and only one bottle opening for the day was considered nonadherent for the day. The adherence estimates for the first and last days the MEMs cap use were excluded as
the adherence data on these days would be partial. The adherence ratio (0–100%) was analyzed and suboptimal
adherence was also defined using 2 cutoffs, >20 and >30% non-adherence. There is no consensus regarding the
threshold of optimal ART adherence. Thus we chose to examine non-adherence rates of 20 and 30% and assume
that those who take at least 80% of their ART would be at low risk of treatment failure while those who take less
than 70% of their HIV medication would have a substantially greater likelihood of failure to achieve or maintain
viral suppression.
ART non-persistence was examined using a 3- and 7-day threshold for permissible gaps. Non-persistence was
quantified as the number of times a participant failed to open their bottle for three or more consecutive days
(i.e., three zeros in a row); this measure was also quantified using seven or more consecutive days of missed
bottle openings. We refer to these as “3-” and “7-day” non-persistence, respectively.
MEMs data were analyzed using two approaches: (1) a “conservative” analysis in which no adjustment to the
recorded MEMs data were made; and (2) an “adjudicated” analysis in which MEMs data were censored based

on participant self-report of non-use of the MEMs cap. The most common reasons for data censoring in the
adjudicated approach were intermittent use of a pillbox and pocketing of doses (e.g., removing the evening dose
of a twice a day medication when taking the morning dose). Conservative results were comparable to
adjudicated results; unless otherwise stated, the adjudicated results are shown.

Psychometric Analyses to Identify Reliable Item Subscales Using Item Response Theory

To evaluate which items included in the Instrument Piloting and Test Phase comprise psychometrically sound
scales, we examined the factor structure of each scale as it was blocked and presented to respondents on the
baseline survey. We used the software IRTPRO 2.0 [[16] ] to compute local dependence (LD) statistics for each
item block from the baseline survey. Large LD values for item pairs suggested that those particular items share
specific variance above and beyond the other items in the survey block. Clusters of items exhibiting large LD
statistics suggested possible underlying factors; we formed subscales based on these suggested factors. We then
calibrated the items and scored respondents, such that each respondent had a single item response theory (IRT)
scale score for each subscale. IRT scale scores represent responses to categorical and ordinal items that have
been transformed into a continuous scale based on each specific response pattern.
Using item-level responses from baseline assessments, we identified reliable subscales based on attitudes, selfreported adherence behavior, and beliefs. To determine which items within a subscale had the most desirable
psychometric properties, we examined trace lines and item discrimination parameters. Items with larger
discrimination parameters are better able to differentiate between people across levels of the underlying factor;
therefore, those items with the greatest discriminating power were considered the strongest candidates for
each subscale.

Statistical Analyses to Predict Medication Adherence from Individual Items

To identify candidate scale items that could be strong predictors of non-adherence and non-persistence, we also
fit penalized regression models using the multivariable lasso selection procedure [[17] ]. The lasso approach is
useful when there are many items to consider in a prediction problem because it avoids model over-fitting.
Models were cross-validated and used to select the lasso penalization tuning parameter for each model.
Two types of predictor variables were used in these analyses, separately: (1) the 148 individual survey items;
and (2) the 12 IRT reliable subscales identified in the prior IRT data analytic step. The 11 contingency survey
items were recoded into three categories prior to analysis (agree, disagree/neutral, does not apply). To predict
the non-adherence ratio the count of non-adherent days was modeled using Poisson lasso regression with
natural-log transformed number of MEMs monitored days included as the model offset term. Non-persistence
was analyzed as a binary outcome (0 episodes vs. 1 or more episodes) and modeled using logistic lasso
regression. Likewise, binary outcomes of non-adherence >20 or >30% were modeled with logistic lasso
regression. In total, the lasso selection was conducted separately for five endpoints: (1) non-adherence rate; (2)
non-adherence >20%; (3) non-adherence >30%; (4) 3-day non-persistence; and (5) 7-day non-persistence.
We used multiple imputation with fully conditional specification. Ordinal items were imputed using predictive
mean matching, binary items were imputed with logistic regression, and 3-category contingency items were
imputed with a generalized logit model. Adherence ratio, 3-day non-persistence, and all fully-observed ordinal
survey items were included in the imputation models when feasible. Models including individual survey items
used ten imputed datasets and individual predicted values were calculated from the average predicted value
over the ten imputed datasets.
We summarized the predictive impact by ranking individual items according to the number of times they were
selected by the lasso method across the five endpoints and ten multiple imputed datasets. Individual items that
ranked within the top ten were selected for a final prediction model. When lasso-selected items were identified,

we matched them to the reliable IRT subscales previously created. We conducted Poisson regression (negative
binomial regression in the case of statistically significant over-dispersion) and logistic regression to obtain
predicted values from combinations of the included IRT subscales and their corresponding items. For nonadherence rate we plotted the “predicted versus observed” rates, and the proportion of predicted values
within ±10% of the observed rate is shown. For each binary outcome, we examined the true positive rate
(sensitivity) versus false positive rate (1-specificity) in a receiver-operator characteristic (ROC) curve and the
area under the ROC curve (AUROCC).
The study participant-specific relative odds of non-adherence on weekends (Saturday or Sunday) as compared to
non-adherence on weekdays was estimated using mixed effects logistic regression with a random intercept for
each participant. The “glmnet” package was used to conduct the lasso analyses in R version 3.1.2; other
statistical analyses were conducted in SAS 9.3 or 9.4.

Results
Participant Characteristics and Disposition

Of 212 patients approached for enrollment to the Instrument Piloting and Testing Phase, 181 (85%) consented,
entered the study, and completed a baseline survey. Eight participants were excluded from the analysis cohort
because there was evidence they used a pill box and not medication bottles on which the MEMs cap was placed
(n = 5) or did not complete the baseline survey (n = 3). The remaining 173 (96% of 181) were considered eligible
for analysis. These participants were monitored by MEMs cap for a median (Q1, Q3) of 92 (86, 97) days (10–90th
percentile: 75–102). A summary of the selected antiretroviral medications for the MEMS cap is provided in
Supplemental Table S1. The most common MEMS monitored medications were tenofovir disoproxil fumarate
(TDF)/emtricitibine (FTC) (29%), TDF/FTC/efavirenz (22%), and TDF/FTC/elvitegravir/cobicistat (12%).
Table 1 presents the characteristics of the study participants. Most participants were African–American and
middle aged; slightly more than a third were women. At study entry, all but two participants were already
receiving ART at the time of study entry, and almost 80% entered the study with an HIV RNA level that was
below the limit of assay detection. The median duration of ART therapy was 8 years, and a variety of ART were
prescribed, with two thirds of patients reporting being on a once-daily regimen and the remainder reporting
being on twice daily regimens. Nearly half of the participants reported a history of depression or bipolar
disorder.

Descriptive Findings for ART Adherence and Persistence

Using the adjudicated MEMs approach (i.e., MEMs data supplemented by respondent self-report), the mean
non-adherence rate (non-adherent days/monitored days) was 22% (SD, 25) over the course of the 3-month
study, with a median (Q1, Q3) of 13% (3, 33). With the conservative approach (i.e., MEMs data only), the
estimated non-adherence rate was similar, with mean (SD) of 25% (26) of days and median (Q1, Q3) of 15% (3,
37) of days. Using the adjudicated approach, 39% of participants (68/173) had a non-adherence rate >20% of
days, and 27% of participants (47/173) had a non-adherence rate >30%. Patient-specific odds of non-adherence
were 30% higher on the weekends compared to weekdays (estimated odds ratio (OR) 1.30, 95% CI: 1.17–1.44).
Many participants persistently opened their MEMS cap as prescribed, with zero episodes of non-persistence.
Nevertheless, at least one episode of non-persistence for 3 days or longer was recorded in 37% of participants
(64/173) during study follow-up, and 17% (29/173) had at least one episode of non-persistence lasting 7 days or
longer.

Findings from the Psychometric Analyses of Subscales Using Item Response Theory

We conducted exploratory factor analyses, followed by assessments of local dependence among item sets,
which resulted in 12 subscales from the baseline assessment with moderate to large IRT marginal reliabilities.
Appendix Table 4 presents the 12 subscales along with their marginal reliabilities. Descriptive analyses generally
showed a negative skew, such that most participants endorsed the upper portions of the scale corresponding to
the “positive” set of choices. Participants acknowledged the importance of social support, cited positive reasons
for medication (subscale: Positivity), did not let the side effects prevent them from taking the medications
(Effects of Medication), and reported trusting their doctors (Trust).

Findings from Predictive Adherence and Persistence Models

For the adherence predictive models we considered 148 baseline survey items for inclusion in both the IRT
subscales and the predictive models of non-adherence and non-persistence. For multivariable analyses of survey
items, data were imputed as described in the methods. Of the reliable IRT subscales, HIV-ASES (confidence in
medication taking), ACTG-ABQ (barriers to adherence, e.g. busy and forgetful), Difficulty, and Positivity each
included one item that ranked in the top ten according to individual item lasso selection; these IRT subscales
were used to form prediction models (Table 2). When lasso selection was applied directly to the 12 continuous
IRT scores ACTG-ABQ was selected across all five endpoints, Difficulty was selected for four endpoints (not 7-day
non-persistence), and Positivity selected for the three adherence endpoints. While HIV-ASES was never selected
when fit as an IRT score, the highest ranked individual predictive item was from this subscale, and thus it was
retained for the final IRT-based prediction models. Additional IRT scores ever selected by lasso were Mode (7day non-persistence), Convenience (3-day non-persistence), and Trust (3-day non-persistence).
The two candidate surveys arising from this work, Lasso-10 and IRT-30, are presented in Appendix Tables 5 and
6, respectively, and their internal prediction performance is shown in Table 2. The Lasso-10 included the top ten
ranked items using lasso selection without regard to IRT subscales (one item from HIV-ASES, one item from
ACTG-ABQ, and eight items novel to this work) with a marginal reliability of.77. The IRT-30 contained 30 items
from four IRT subscales and had a marginal reliability of.90. These two potential surveys have four items in
common. The ten-item survey takes approximately 5 min to complete and the 30-item survey takes
approximately 10 min (note the yes/no items were less time consuming than those on a Likert scale). The top
ten individual items, according to lasso ranking alone, performed well with respect to internal prediction
(AUROCCs: 77–89%). A calculator for predicted probability of non-adherence and non-persistence outcomes
using the items in Lasso-10, is available online (http://www.med.unc.edu/ncaidstraining/adherence/forproviders), providing a short survey that would be suitable in a clinical setting.
The final IRT prediction models included either the IRT scores or items from HIV-ASES, ACTG-ABQ, Difficulty, and
Positivity (30 items total). Internal prediction of the observed non-adherence ratio within a threshold of ±10%
was achieved for 37% of individuals when the 30-item scale was fit using its four continuous IRT scores, and for
47% of individuals when fit using the 30 individual items from the IRT-30 scale (Supplementry Fig. S1). Looking at
dichotomized outcomes with the selected IRT subscales fit as IRT scores, the AUROCC ranged from 63 to 77%
across the dichotomized outcomes. There was numerically stronger prediction when we fit the 30 chosen
individual items (AUROCCs: 84–86%, as shown in Table 2) compared to fitting these same items using their
respective IRT scores. We chose to keep IRT subscales intact within the final IRT-30 survey because these items
were calibrated as a set in the IRT analyses. The purpose of IRT is to define and evaluate scales based on sets of
items measuring a common construct; selecting items from different subscales and combining them into a new
scale changes the construct that is being measured. To preserve the original substantive interpretations of the
subscales, we did not omit or shuffle items across the IRT subscales. Among the chosen IRT subscales, ACTG-ABQ
(adherence barriers) was most strongly associated with non-adherence (p-values < .001) and non-persistence

outcomes (p-values = .02). A higher ACTG-ABQ score was associated with greater odds of both non-adherence
and non-persistence (Table 3).

Discussion
Using a comprehensive scale development approach we identified two new scales, both of which were reliable
and predictive of medication adherence and persistence among a diverse group of patients living with HIV
infection. Our formative work included extensive interviews with service health care providers and focus groups
of people living with HIV infection, and set a strong foundation upon which to introduce a new candidate set of
items to existing sets from the literature.
The candidate items and previously existing items were combined in a survey and measured in a cohort of
patients receiving HIV care and, in general, taking HIV therapy for several years. Among these participants we
found that adherence to ART was suboptimal approximately one quarter of the time, with 27% of participants
missing doses more than 30% of the days they were observed. Further, 17% had at least a week-long break in
therapy during study follow-up.
For prediction of suboptimal adherence and non-persistence outcomes we identified a new ten-item scale using
the lasso variable selection method. Eight of the top ten items for prediction of adherence and persistence were
novel to this study. This ten-item scale had marginal reliability of.77, which is reasonable reliability for a scale of
this length, and had area under the ROC curve internal prediction values of 84.6 and 88.6% for >30% nonadherence and 7-day non-persistence, respectively. This new scale takes approximately 5 min to complete and
has potential for future evaluation and clinical use.
When examining the ability of items derived from our formative work and from the literature to predict lapses in
therapy, we found that those assessing perceived confidence in medication taking and self-reported barriers to
adherence were strongest in independently predicting non-adherence. Items related to barriers to adherence
(e.g., affordability, integration with schedule and activities) were best able to predict independently higher
levels of non-adherence, as well as 3- and 7-day non-persistence. Self-reported adherence measured using the
visual analog scale [[15] ] at study entry did not improve the predictive capability of the selected multivariable
models.
Unlike many scale development studies, we further applied an in-depth IRT psychometric approach to identify
new item subscales that were both short and reliable. Using this approach, we identified new IRT subscales and
ultimately a 30-item scale with high marginal reliability (.90) and internal predictive capability (as measured by
area under the ROC curve) similar to our ten-item scale. This 30-item scale includes two previously existing
subscales plus two novel subscales and takes approximately 10 min to complete. Arriving at and interpreting the
psychologically meaningful construct is the IRT goal, while purely predicting medication adherence and
persistence outcomes is the goal of the lasso method. Each approach contributes unique information, and one
would not necessarily expect the two approaches to converge on the same sets of items. When interpreted side
by side, these two methods can help identify which sets of items measure a common psychological construct,
and which individual items are the strongest predictors of adherence.
Interestingly, the IRT subscales derived from the formative work were short and reliable, but were weaker at
predicting adherence and persistence as those previously developed in other populations [[13] , [14] ]. This
finding may reflect a disconnect between what people living with HIV report as being facilitators and barriers to
adherence and what actually influences medication taking. The longest of our new IRT subscales had only six
items, compared to 9 and 12 items in the ACTG-ABQ and HIV-ASES subscales, respectively, also suggesting that
our formative work produced new items that spanned across several psychological constructs. It should also be
noted that the IRT scales were formed not based on their ability to predict adherence, but rather on the degree

to which responses on individual items co-vary to measure a common psychological construct. While a set of
items measuring disparate constructs may predict medication adherence well, these items do not necessarily
produce a unidimensional, reliable IRT subscale. To be considered an IRT subscale, it is assumed that the same
underlying psychological construct influences the item responses within the set. Likewise, the item set most
predictive of adherence (i.e., the ten-item scale identified using the lasso approach) is not necessarily a set of
items that forms a psychologically meaningful construct.
A major strength of this investigation was the economic, educational, racial/ethnic, and gender diversity of our
studied sample. In addition, this contemporary cohort taking HIV medications reflects the characteristics of
patients of the foreseeable future; most were on once-daily therapy. This study had high retention rates, and
there were relatively little missing data. Our candidate items were developed via extensive formative research
conducted with individuals not unlike those studied. In addition, items from select instruments that had been
previously reported to be predictive were included in the survey battery. As there is some variability in the
methods used to estimate adherence using MEMs, we opted to conduct analyses using two approaches: a strict
conservative use of the MEMs cap openings such that only the MEMs data were evaluated, and an adjudicated
use that included ‘forgiveness’ for explained non-openings of the cap. We found the difference between the two
approaches to be minimal—a finding that can provide guidance to future use and analysis of MEMs data.
Aspects of the study that were strengths were also limitations. The MEMS indices do not tell specifically that
medication was actually ingested but rather that a particular medication bottle cap was opened. Other study
limitations include the fact that we cannot say which items would perform best with an external set of data, as
we used the complete dataset to identify the predictive items and sets. While our study sample size was
relatively large, this investigation would benefit from an external validation of the final ten-item and 30-item
inventories. Follow-up, on study HIV RNA data were not uniformly available and therefore could not be
described. Finally, we tracked study participants for 3 months; longer term patterns of medication adherence
and persistence are worthy of additional study.
In summary, as HIV therapy continues to require daily self-administration of one or more oral medications,
adherence and persistence to these therapies continues to be essential to treatment success and long term wellbeing. We identified a series of questions that could be used to elicit responses that would be predictive of
future ART adherence and persistence including a ten-item battery of items most predictive of these outcomes,
as well as a 30-item battery reflective of the psychological constructs found to be the root of medication-taking
in this population. These batteries may be useful to clinicians and researchers, respectively, and others seeking
to predict ART taking behaviors. The ability to identify individuals at risk for suboptimal adherence can be highly
valuable in directing counseling and other supportive measures to achieve and maintain control of HIV.
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Table 1. Characteristics of study participant (n = 173)
Characteristic
Age (years)
Median (Q1, Q3)
Mean (SD)
Min–max
Gender
Male
Female
Transgender

Statistics
48 (39, 53)
46 (11)
21–74
108 (63%)
61 (35%)
3 (2%)

Race/ethnicity (check all that apply)
American Indian
Black
Hispanic
White
More than 1 race

5 (3%)
140 (81%)
3 (2%)
28 (16%)
6 (3%)

Education level
Less than high school
High school
College or beyond

43 (25%)
59 (34%)
70 (41%)

Insurance status (check all that apply)
Unemployed/disabled
Insured for clinic visits
Insured for medication
Private health
Medicare
Medicaid
ADAP
State-sponsored
Other government plan
Other plan
Years since HIV?diagnosis

104 (60%)
148 (86%)
155 (92%)
11 (6%)
43 (25%)
83 (48%)
56 (33%)
9 (5%)
12 (7%)
24 (14%)

Median (Q1, Q3)
Min–max
Ever take HIV medications
Number of ART medications
Median (Q1, Q3)
Min–Max
Dosing frequency from self-report
Once daily
Twice daily
Dosing frequency from MEMs
Once daily
Twice daily
Years since ART start
Median (Q1, Q3)
Min–max
Type of pharmacy (check all that apply)
Mail pharmacy
Local pharmacy
Clinic pharmacy
Other pharmacy (e.g. home delivery)
CD4 count (cells/mm3)
Median (Q1,Q3)
Mean (SD)
Min–max
HIV-1 RNA\50 copies/mL
Adherence visual analog scale, past 30 days
Median (Q1, Q3)
Mean (SD)
Min–max
Reported 100% on adherence visual analog scale
Depression/bipolar diagnosis

12.6 (4.6, 18.5)
0.0–30.4
168 (97%)
2 (1, 3)
0–5
115 (68%)
54 (32%)
142 (82%)
31 (18%)
8.2 (3.0, 15.6)
0.0–28.3
82 (48%)
70 (41%)
20 (12%)
9 (5%)
565 (350, 770)
605 (334)
10–2097
132 (79%)
100 (96, 100)
96 (12)
0–100
103 (61%)
79 (46%)

Participant characteristics were summarized with a complete-record approach (missing data excluded). Missing
data: age (n = 4), gender, education level, insurance status, number of ART medications, type of pharmacy (n = 1
each), years since HIV diagnosis (n = 6), years since ART start (n = 23), CD4 cell count (n = 9), HIV-1 RNA (n = 5),
and adherence visual analog scale (n = 4)
Table 2 Prediction of non-adherence and non-persistence
Endpoint

Events/total

AUROCC IRT
scoresa

Events/total

AUROCC IRT
30b,c

AUROCC Lasso
10c,d

Non-adherence
>20%
Non-adherence
>30%
Non-persistence 3day
Non-persistence 7day

66/169

.700

68/173

.861

.813

45/169

.766

47/173

.841

.846

62/169

.633

64/173

.838

.766

28/169

.696

29/173

.835

.886

4 df
30 df
13 df
HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ modified version of the AIDS clinical trials group
adherence barriers questionnaire, Difficulty, Positivity additional ESTEEM items created based on stakeholder and
consumer interviews, AUROCC area under receiver-operator characteristic curve, df degrees of freedom, IRT item response
theory, Lasso least absolute shrinkage and selection operator
a HIV-ASES, ACTG-ABQ, Difficulty and Positivity fit as 4 continuous IRT scores; n = 169 (4 subjects with missing IRT scores
excluded)

b HIV-ASES, ACTG-ABQ, Difficulty and Positivity fit using the 30 Likert-type survey items included in these IRT subscales
c n = 173, average AUROCC over ten imputations is shown
d Top ten items using lasso selection (includes three contingency items with three categories each, hence 13 df)

Table 3 Association between IRT Scores and adherence and persistence (n = 169)
Rate ratio

95% CI

1.25
1.61
1.08
0.86

1.01
1.25
0.86
0.69

Odds ratio

95% CI

1.11
2.18
1.22
0.70

0.76
1.38
0.78
0.45

Non-adherence >30%
HIV-ASES
ACTG-ABQ
Difficulty
Positivity

1.44
2.79
1.37
0.71

3 day non-persistence
HIV-ASES
ACTG-ABQ
Difficulty
Positivity
7 day non-persistence
HIV-ASES
ACTG-ABQ
Difficulty
Positivity

Non-adherence rate
HIV-ASES
ACTG-ABQ
Difficulty
Positivity

Wald Chi square

P value

4.38
13.51
0.40
1.66

.04
<.001
.53
.20

Wald Chi square

P value

1.61
3.43
1.89
1.09

0.29
11.30
0.76
2.49

.59
<.001
.38
.11

0.93
1.71
0.82
0.42

2.25
4.57
2.28
1.21

2.65
16.70
1.46
1.58

.10
<.001
.23
.21

0.88
1.67
1.31
0.97

0.62
1.08
0.85
0.63

1.27
2.58
2.04
1.50

0.45
5.27
1.48
0.02

.50
.02
.22
.89

1.25
1.87
1.49
1.19

0.77
1.11
0.83
0.67

2.03
3.13
2.68
2.14

0.81
5.55
1.81
0.35

.37
.02
.18
.55

1.53
2.07
1.35
1.08

Non-adherence >20%
HIV-ASES
ACTG-ABQ
Difficulty
Positivity

Bold values indicate statistical significance HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ
modified version of the AIDS clinical trials group adherence barriers questionnaire, Difficulty, Positivity
additional ESTEEM items created based on stakeholder and consumer interviewsa Multivariable models were fit
using continuous IRT scores for HIV-ASES, ACTG-ABQ, Difficulty and Positivity. A non-adherence rate ratio was
estimated using negative binomial regression (dispersion estimate = 1.33, 95% CI 1.07–1.65), and odds ratios
were estimated using logistic
regression
Table 4 Item content, number of items and marginal reliabilities for 12 item response theory (IRT) subscales
IRT subscale name and items

Total
items

HIV-ASES/confidence: In the next 30 days, how confident are you that you can:

12

IRT
marginal
reliability
.75

1. Stick to taking your HIV medicines even when side effects begin to interfere with daily
activities?
2. Integrate taking your HIV medicines into your daily routine?
3. Integrate taking your HIV medicines into your daily routine even if it means taking them
around other people who don’t know you are HIV-infected?
4. Stick to your HIV medicine schedule even when your daily routine is disrupted?
5. Stick to your HIV medicine schedule when you aren’t feeling well?
6. Stick to your HIV medicine schedule when it means changing your eating habits?
7. Continue with taking your HIV medicines even if doing so interferes with your daily activities?
8. Continue with the HIV medicines plan your physician prescribed even if your T-cells drop
significantly in
the next 3 months?
9. Continue with the HIV medicines even when you are feeling discouraged about your health?
10. Continue with taking your HIV medicines even when getting to your clinic appointments is a
major hassle?
11. Continue with taking your HIV medicines even when people close to you tell you that they
don’t think that it is doing any good?
12. Continue taking your HIV medicines even if it doesn’t make you feel better?
Social support
1. I have some very close people in my life who would do almost anything for me
2. My support (friends, family) give me strong emotional support
3. I have friends who give me strong emotional support
4. I have family who give me strong emotional support
Well-informed/doctor-patient relationship
1. It makes me feel strong when I get a positive health report from my doctor
2. I would tell the doctor if I weren’t taking my medication
3. I have come to accept my HIV diagnosis
4. I have learned a great deal from reading about HIV/AIDS
5. I am comfortable asking my doctor questions about my disease
Difficulty/interference of medication
1. I have physical health problems that make it hard for me to take my HIV meds regularly
2. I have mental health problems that make it hard for me to take my HIV meds regularly
3. It is hard for me to keep track of my HIV meds
5. HIV medications interfere with my ability to have fun
Positivity about medication
1. I feel pretty healthy when I take my HIV medications
2. When I take my HIV medications, I feel better about myself
3. Taking my HIV medications gives me hope
4. Taking HIV medication reminds me to take care of my personal health
Management of medication
1. I’d take my HIV meds more consistently if my doctor(s) helped me figure out if I was actually
ready to take the HIV meds
2. I’d take my HIV meds more consistently if my doctor(s) told me more about the problems I
might face with getting my HIV pills (such as cost)
3. I’d take my HIV meds more consistently if my doctor(s) helped me balance taking my HIV
meds with my other health needs (e.g., heart, weight, mental health, substance abuse)
Effects of medication
1. I’d take my HIV meds more consistently if my doctor(s) taught me how the HIV meds help me
stay healthy
2. I’d take my HIV meds more consistently if my doctor(s) showed me how the HIV meds affect
my lab/blood results
3. I’d take my HIV meds more consistently if my doctor(s) were very clear with me about the
side effects of my HIV medication
Trust: do you trust your health care provider:
1. To offer you high quality medical care?

4

.83

5

.75

5

.83

4

.80

3

.82

3

.84

4

.55

2. To be more concerned about your health than the time, effort, and costs of treating you?
3. To prescribe the best HIV medications?
ACTG-ABQ: In the past month, have you missed taking your medications because you: Please check
9
.90
one box
for each question.
1. Forgot?
2. Didn’t get prescription; ran out of pills?
3. Busy doing other things (e.g., working, trying to survive, getting food)?
4. Having to wake up very early to go to work and no time to eat?
5. Was too busy at work, school, or home?
6. Didn’t want to bring my pills to social activities (restaurant, friend’s home)?
7. Wanted to have a free day without pills?
8. Lost track of time?
9. Didn’t have a good night sleep?
Pleasantness
3
.88
1. I’d take my HIV meds more consistently if the pills were more pleasant to take
2. I’d take my HIV meds more consistently if the pills were smaller.
3. I’d take my HIV meds more consistently if the pills tasted more like candy
Mode of administration
4
.76
1. I’d take my HIV medications more consistently if I could take the pills in a liquid form rather
than tablets
2. I’d take my HIV medications more consistently if they were a shot instead of pills
3. I’d take my HIV medications more consistently if they were a shot taken once a month
4. I’d take my HIV medications more consistently if I did not have to take them in a special way
(e.g., with
food, on an empty stomach).
Convenience
6
.90
1. I’d take my HIV meds more consistently if I felt fewer side effects
2. I’d take my HIV meds more consistently if I had fewer pills to take
3. I’d take my HIV meds more consistently if the meds were cheaper
4. I’d take my HIV meds more consistently if they were dosed less frequently
5. I’d take my HIV meds more consistently if I had been told more about the side effects before
taking the pills in the first place
6. I had special dispensers to help me keep track of the pills
HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ modified version of the AIDS clinical trials group
adherence barriers questionnaire
Additional ESTEEM Items created based on stakeholder and consumer interviews. Item subsets were identified using
exploratory analyses for ordered categorical variables, measures of item dependence, item trace lines and information
functions. Items were rated on a scale ranging from
1 = strongly disagree to 5 = strongly agree

Table 5 Final ten-item scale
Lasso-10 marginal reliability = .77

Response options

Item
origin

Lasso
prediction
rank

Scale ranging from 0
(‘‘cannot do at all’’) to 10
(‘‘completely certain can
do’’)

ASES

1

Items
1. In the next 30 days, how confident are you that you can continue
with the HIV medicines even when you are feeling discouraged about
your health?

2. In the past month, have you missed taking your HIV medications
No/yes ABQ because you forgot?
3. I find it easy to take my HIV meds with the other medication I take

No/yes

ABQ

3

(a) Strongly disagree,

New

7

4. I have reduced my illegal drug use because I am taking my HIV
medications

(b) Disagree,

New

8

New

2

New
New
New

4
5
6

5. If I could stop taking illegal drugs, I would be able to take my HIV
medications regularly
6. People often make me feel badly about being HIV?
7. Taking pills everyday is not a big deal
8. It is hard for me to keep track of taking my HIV meds

(c) Neither disagree nor
agree,
(d) Agree,
(e) Strongly agree,
(f) Does not apply
(1) Strongly disagree,
(2) Disagree,
(3) Neither disagree nor
agree,
(4) Agree,
(5) Strongly agree

9. Taking my HIV medications gives me hope
New
9
10. I can count on my family and friends to make sure I am taking my
New
10
HIV meds consistently
HIV-ASES the HIV treatment adherence self-efficacy scale. ACTG-ABQ modified version of the AIDS clinical trials group
adherence barriers questionnaire. New items created based on stakeholder and consumer interviews in the present study.
This ten-item survey has been ordered to group items with similar response scales together. Lasso prediction rank is shown
for research purposes, with #1 being the most predictive item in the present study, as summarized over non-adherence and
non-persistence outcomes

Table 6 Final 30-item IRT scale
IRT-30 scale marginal reliability = .90
Items
In the next 30 days, how confident are you that you can:
(11-point scale from 0 [cannot do at all] to 10 [completely certain can do])
1. Stick to taking your HIV medicines even when side effects begin to interfere with daily activities?
2. Integrate taking your HIV medicines into your daily routine?
3. Integrate taking your HIV medicines into your daily routine even if it means taking them around other
people who don’t know
you are HIV-infected?
4. Stick to your HIV medicine schedule even when your daily routine is disrupted?
5. Stick to your HIV medicine schedule when you aren’t feeling well?
6. Stick to your HIV medicine schedule when it means changing your eating habits?
7. Continue with taking your HIV medicines even if doing so interferes with your daily activities?
8. Continue with the HIV medicines plan your physician prescribed even if your T-cells drop significantly in
the next 3 months?
9. Continue with the HIV medicines even when you are feeling discouraged about your health?
10. Continue with taking your HIV medicines even when getting to your clinic appointments is a major
hassle?
11. Continue with taking your HIV medicines even when people close to you tell you that they don’t think
that it is doing any
good?
12. Continue taking your HIV medicines even if it doesn’t make you feel better?
In the past month, have you missed taking your medications because you: Please check one box for each
question (No/Yes)
13. Forgot?
14. Didn’t get prescription; ran out of pills?

Item
origin

ASES
ASES
ASES
ASES
ASES
ASES
ASES
ASES
ASES
ASES
ASES
ASES
ABQ
ABQ

15. Busy doing other things (e.g., working, trying to survive, getting food?)?
ABQ
16. Having to wake up very early to go to work and no time to eat?
ABQ
17. Was too busy at work, school, or home?
ABQ
18. Didn’t want to bring my pills to social activities (restaurant, friend’s home)?
ABQ
19. Wanted to have a free day without pills?
ABQ
20. Lost track of time?
ABQ
21. Didn’t have a good night sleep?
ABQ
5-point Likert scoring for agreement*
22. I have physical health problems that make it hard for me to take my HIV meds regularly
Difficulty
23. I have mental health problems that make it hard for me to take my HIV meds regularly
Difficulty
24. It is hard for me to keep track of my HIV meds
Difficulty
25. It’s hard for me to take my HIV meds when I am taking other types of medications
Difficulty
26. HIV medications interfere with my ability to have fun
Difficulty
27. I feel pretty healthy when I take my HIV medications
Positivity
28. When I take my HIV medications, I feel better about myself
Positivity
29. Taking my HIV medications gives me hope
Positivity
30. Taking HIV medication reminds me to take care of my personal health
Positivity
HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ modified version of the AIDS clinical trials group
adherence barriers questionnaire, ESTEEM additional items created based on stakeholder and consumer interviews
* The following items are from our new ‘‘Difficulty/Interference of Medication’’ and ‘‘Positivity about Medication’’ IRT
Subscales
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